REGISTER HERE.

Join Axel Grothey, MD, Geoffrey Ku, MD, and Kohei Shitara, MD, for a web broadcast featuring the identification and development of targeted therapies that address specific driver alterations—such as HER2/3 amplification and PD-L1 amplification, among others—has reshaped our approach to cancers of the gastrointestinal tract, opening opportunities for personalized medicine for patients with advanced disease. This innovative educational activity will highlight the importance of molecular testing, help synthesize the latest advances of novel therapeutics, and provide practical guidance on the role and use of current and emerging molecular-directed strategies in gastric, colorectal, and other GI cancers. Brief scientific segments will be coupled with "Translating Science, Transforming My Practice" segments, which will offer a personal look at the way experts translate and interpret emerging scientific data as they look to adopt newer therapeutic strategies into practice and optimally navigate patient care for individuals with GI cancers.

AGENDA

• Welcome and Introduction
• Approaching GI Cancer With Precision: Examining the Rationale and Significance of Molecularly Targeted Therapy
• Evolving the Standard of Care for Gastric Cancer With Novel HER2- and Other Molecularly Targeted Approaches
• Preparing for the Next Wave of Advances in Colorectal, Biliary, and Pancreatic Cancers: Targeting HER2 and Other Critical Oncodrivers
• Synthesis, Reflections, and Conclusions

TARGET AUDIENCE

This activity has been designed to meet the educational needs of medical and gastrointestinal oncologists and other clinicians involved in the management of gastrointestinal cancer.

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants should be better able to:

• Describe the rationale for a biomarker-driven approach to therapy in gastric, colorectal, and other GI cancers, such as the use of HER2, BRAF, NTRK, PD-L1, FGFR, MSI, and TMB status
• Review expert and guideline-based recommendations to accurately test for biomarkers in GI cancers that can guide appropriate treatment selection
• Assess the latest safety and efficacy data on established and emerging targeted therapeutics for gastric, colorectal, and other GI cancers, such as HER2-directed antibody-drug conjugates, BRAF inhibitors, NTRK inhibitors, FGFR inhibitors, PARP inhibitors, checkpoint inhibitors, and others
• Develop personalized treatment plans, utilizing validated or emerging therapeutic strategies, for patients with advanced GI cancers based on treatment history, biomarker status, performance status, and patient preferences

ACCREDITATION

This CME/MOC activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.
The Medical Learning Institute, Inc. designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For more information please visit the official event page.